Replies to post #225999 on Biotech Values

[CT]

FGEN subject to remaining overhang of doubt regarding MACE data (+adcom). Then on the business side, it remains to be seen 1) if FGEN can access the NDD patient population and 2) if/how China will cover roxa for patients. Just my quick thoughts.